Kathleen Tregoning Increases Stake in Spero Therapeutics

Kathleen Tregoning, a notable insider, has purchased 10,000 shares of Spero Therapeutics, Inc. (NasdaqGS: SPRO) on June 23, 2026. This insider transaction reflects a continued interest in the biotechnology company, which focuses on developing treatments for multi-drug resistant bacterial infections.

Insider Buying and Selling at Spero Therapeutics, Inc.

On June 23, 2026, several insiders, including Kathleen Tregoning, acquired shares in Spero Therapeutics. Jackson Scott Thomas, John Pottage Jr., Milind Deshpande, Cynthia Smith, Patrick V.J.J. Vink, and Frank Thomas each bought 10,000 to 20,000 shares. These transactions were not conducted under any pre-planned trading arrangements, indicating a direct interest in the company's performance.

Other Institutional Activity in Spero Therapeutics

Among institutional investors, Two Sigma Investments significantly increased its holdings in Spero Therapeutics by 513,061 shares, marking a 137.7% boost to a total of 885,631 shares valued at approximately $2.07 million. Meanwhile, Vanguard Capital Management opened a new position with 1,799,880 shares worth about $4.21 million. Renaissance Technologies reduced its stake by 90,287 shares, resulting in a 7.1% decrease, ending with 1,189,235 shares valued at around $2.78 million.

Spero Therapeutics, Inc. Stock Up 68.3%

Shares of Spero Therapeutics traded near $2.02 on Friday. The company, with a market cap of approximately $117 million, has a P/E ratio of 7.48 and a beta of 1.456. The stock has seen a 52-week low of $1.80 and a high of $3.22, with a 50-day moving average of $2.63 and a 200-day moving average of $2.40. Spero's strong liquidity is reflected in its current ratio of 10.496 and a quick ratio of 10.234, though it carries a debt-to-equity ratio of 4.674.

Analysts Set New Price Targets

HC Wainwright & Co. reiterated its 'buy' rating for Spero Therapeutics with a price target of $5.00 on January 30, 2025. The consensus among analysts suggests a 'hold' recommendation, with an average target price of $4.00 based on one analyst's opinion.

About Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. It focuses on developing new treatments for multi-drug resistant bacterial infections and rare diseases. The company's leading product candidate is Tebipenem HBr, an oral antibiotic for complicated urinary tract infections. Spero has partnerships with Meiji Seika Pharma and Everest Medicines for the development and commercialization of its products in various regions.

Bottom Line

The recent insider buying activity at Spero Therapeutics, along with institutional interest, highlights ongoing confidence in the company's potential. While the stock has experienced some volatility, its focus on addressing unmet medical needs positions it as a watchful player in the biotech sector. Investors should note that these insights are based on past filings and may not reflect current positions.